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Abstract: Circular RNAs (circRNAs), formed by nonsequential back-splicing of pre-messenger 
RNA (pre-mRNA) transcripts, have been widely concerned in recent years. With advances in 
high-throughput RNA sequencing (RNA-seq) technology, previous work has revealed that a 
large number of circRNAs, which are endogenous, abundant and stable in mammalian cells, 
may be involved in atherosclerotic vascular disease risk, neurological disorders, prion diseases 
and carcinomas. Remarkably, interaction between circRNAs and microRNA has already been 
observed to perform a significant role in a variety of cancers, including gastric cancer and col-
orectal cancer. Recent work has suggested that circRNAs may play critical roles in the initiation 
and development of cancers and could become potential new biomarkers for cancers. Herein, 
we review the current understanding of the roles of circRNAs in cancers and the potential 
implications of circRNAs in cancer-targeted therapy.
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Introduction
Circular RNAs (circRNAs), a special class of endogenous noncoding RNAs, were 
identified in the early 1990s as transcripts and continued to be reported expressed in 
viruses, plants, archaea and animals.1–3 Unlike linear RNAs, which are terminated with 
5′ caps and 3′ tails, circRNAs present in a circular form whose 3′ head and 5′ tail ends 
covalently bond together.4 Recent reports revealed that circRNAs could function as 
competing endogenous RNAs or microRNA sponges, regulating alternative splicing 
or transcription and modulating the expression of parental genes.5–7
With advances in high-throughput RNA sequencing (RNA-seq) technology, 
recent work has revealed that a large number of circRNAs, which are endogenous, 
abundant and stable in mammalian cells, may be involved in atherosclerotic vascular 
disease risk, neurological disorders, prion diseases and carcinomas.8–12 Remarkably, 
interaction between circRNAs and microRNA has already been observed to perform 
a significant role in a variety of cancers, including gastric cancer and colorectal 
cancer, which illuminates pathways to provide diagnostic or predictive biomarkers 
for cancers.13 For example, Sand et al confirmed a total of 322 circRNAs (143 up- and 
179 downregulated) expressed in cutaneous squamous cell carcinoma, and a total of 
1603 microRNA response elements (MREs) were found to be part of the differentially 
expressed circRNAs, which suggested that circRNAs play an important role in tumor 
formation by interfering with relevant microRNAs. Additionally, this study group 
analyzed microarray circRNA expression profiles and identified 23 upregulated and 
48 downregulated circRNAs with 354 MREs in the basal cell carcinoma (BCC) as 
well.14 Taken together, these findings indicated that circRNAs have great potential to 
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become new clinical diagnostic and prognostic markers and 
provide new insights into the treatment of carcinoma.
In this review, we briefly delineate the current understand-
ing of the roles of circRNAs and emphasize its potential 
implications in cancer-targeted therapy.
Categories of circRNAs
circRNAs, which form a covalently closed continuous loop, 
are involved in transcriptional and posttranscriptional gene 
expression regulation.15 circRNAs can be generated from any 
region of the genome, resulting in a great diversity of lengths. 
Like the classification system of long noncoding RNAs 
(lncRNAs), Qu et al classified circRNAs into five types based 
on their genomic proximity to the neighboring gene: 1) sense 
or exonic, if it originates from one or more exons of the linear 
transcript on the same strand; 2) intronic, if it arises from an 
intron of the linear transcript; 3) bidirectional or intragenic, 
if it is transcribed from the same gene location of the linear 
transcript but in close genomic proximity; 4) antisense, if it 
overlaps one or more exons of the linear transcript on the 
opposite strand; and 5) intergenic, if it is located between 
the genomic interval of two genes.16 Beyond this type of 
classification, another sort of way is established based on 
the mechanism.4 First, circular viral RNA genomes could 
be ligated to form 3′,5′- or 2′,5′-phosphodiester bonds with 
the involvement of host cellular enzymes. Second, circRNA 
midbodies can be produced during permuted transfer RNA 
(tRNA) biogenesis in algae and archaea or ribosomal 
RNA (rRNA) processing. Third, a large amount of housekeep-
ing noncoding RNAs, such as the ribozyme RNase P, were 
all recognized in circular forms in archaea. Finally, abundant 
circRNAs may derive from spliced introns and exons.
Biological functions of circRNAs
circRNAs function as competing 
endogenous RNAs or microRNA 
sponges
circRNAs have been confirmed to function as microRNA 
sponges or potent competing endogenous RNA molecules, 
thereby influencing the posttranscriptional actions of 
microRNAs as suppressors of the translation in recent litera-
ture, in which the association between circRNAs and miR-7 
was reported most frequently.17,18 The first microRNA sponge 
identified was human ciRS-7, which has been detected to be 
associated with cervical cancer, neuroblastoma, astrocytoma 
and renal cell and lung carcinoma.19 The overexpression of 
ciRS-7 acts as a microRNA sponge, arresting miR-7 and 
therefore elevating the level of miR-7 targets, which regulates 
the epidermal growth factor receptor (EGFR) expression that 
further regulates cell growth, proliferation, differentiation 
and signaling in human cancer cells.20 Similarly, another 
cir-ITCH, derived from the ITCH gene, presents a sequence 
enriched with three microRNA-binding sites (miR-7, miR-17 
and miR-214) in esophageal squamous cell carcinoma 
(ESCC).21 Additionally, hsa_circ_001569 was selected as a 
potential regulator of colorectal cancer progression and had 
an interaction with miR-145.19 Therefore, the circ-miRNA 
axis, regardless of promotion or suppression, played an 
important role in cancer-related pathways and worth further 
study (Figure 1).
circRNAs regulate alternative splicing or  
transcription
Previous studies have suggested that circRNAs are compet-
ing with alternative splicing or transcription. For example, 
Ashwal-Fluss et al demonstrated that circMbl is generated by 
the second exon of the splicing factor muscleblind (MBL), 
which competes with canonical pre- messenger RNA (pre-
mRNA) splicing. circMbl and its flanking introns contain 
conserved muscle blind-binding sites, which are strongly 
and specifically bound by MBL. Modulation of MBL levels 
strongly affects circMbl biosynthesis, and this effect is depen-
dent on the MBL-binding sites.5 Therefore, this suggests that 
circRNAs can function in gene regulation by competing with 
linear splicing.
circRNAs regulate the expression of 
parental gene
Recent advances have revealed that circRNAs could regu-
late the expression of parental genes. Still taking cir-ITCH 
Figure 1 Mechanism of circRNAs functioning as competing endogenous RNAs or 
miRNA sponges.
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circRNAs in clinical application of carcinomas
as an example, Li et al found that both cir-ITCH and the 
3′-untranslated region (UTR) of ITCH share some microRNA-
binding sites. Further study indicated that the interactions of 
cir-ITCH with miR-7, miR-17 and miR-214 might increase 
the level of ITCH. As a result, it could be speculated that 
exon-only circRNA may fulfill regulatory functions in the 
cytoplasm, whereas intronic circRNAs seem to be efficient 
for transcriptional regulation in the nucleus.21
Correlation between circRNAs and 
carcinomas
circRNAs have been reported to be involved in many human 
diseases, especially in carcinomas. Recent works have 
suggested that circRNAs may play important roles in the 
initiation and development of cancers and could potentially 
become new biomarkers for cancers. Up to date, the most 
frequently studied were that circRNAs mainly serve as 
microRNA sponges to regulate gene expression. MicroRNAs 
regulate a variety of essential biological functions such 
as cellular differentiation, apoptosis and proliferation and 
thus play a critical role in cancer progression. Based on 
these clues, circRNAs were found to be closely related to the 
development of a variety of cancers, all of which are listed 
in Table 1. In this review, we have listed the expression of 
circRNAs in various types of cancers and provide potential 
implications in cancer-targeted therapy (Table 1).
Previous studies revealed that circRNAs showed large 
capabilities in gene regulation by playing microRNA sponge 
effects. Some circRNAs present as a downward trend to 
regulate the pathways. For instance, hsa_circ_002059, a 
typical circRNA, was first found to be significantly down-
regulated in gastric cancer tissues compared with paired 
adjacent nontumor tissues, and further research found that 
lower expression levels of hsa_circ_002059 in plasma were 
significantly correlated with distal metastasis, tumor–node–
metastasis (TNM) stage, gender and age, which might be 
a potential novel and stable biomarker for the diagnosis of 
gastric carcinoma.22 In a study of lung cancer, the expres-
sion of cir-ITCH was significantly decreased in lung cancer 
tissues. Ectopic expression of cir-ITCH markedly elevated 
its parental cancer-suppressive gene, ITCH, expression and 
inhibited proliferation of lung cancer cells.23 Altogether, these 
findings suggested that circRNAs may play an inhibitory 
role in some cancer progression by enhancing its parental 
gene expression.
However, not all circRNAs play a downward regulation in 
cancer progress. Yu et al demonstrated that Cdr1as expression 
was upregulated in hepatocellular carcinoma (HCC) tissues 
compared with the adjacent nontumor tissues. Moreover, 
overexpression of miR-7 could suppress the direct target gene 
CCNE1 and PIK3CD expression. Knockdown of Cdr1as 
suppressed the expression of miR-7 and also inhibited the 
CCNE1 and PIK3CD expression. Furthermore, knockdown 
of Cdr1as suppressed the HCC cell proliferation and invasion 
through targeting miR-7, suggesting that Cdr1as acted as an 
oncogene partly through targeting miR-7 in HCC.24 Shang 
et al also did a study of circRNAs in HCC and reported 
that three circRNAs played roles (hsa_circ_0000520, 
hsa_circ_0005075 and hsa_circ_0066444) in HCC and 
only hsa_circ_0005075 exhibited significant difference in 
expression between HCC and normal tissues. The hsa_
circ_0005075 expression correlated with HCC tumor size 
and showed good diagnostic potential.25 Subsequently, Zhong 
et al used microarray assay to screen circRNA expression 
profiles of bladder carcinoma and predicted that circTCF25 
could downregulate miR-103a-3p and miR-107, increase 
CDK6 expression and promote proliferation and migration 
in vitro and in vivo, suggesting that circTCF25 might be a 
new promising marker for bladder cancer.26
Intriguingly and strikingly, Xuan et al investigated the 
expression of circRNAs in four paired laryngeal squamous 
cell cancer (LSCC) tissues and adjacent nontumor tissues by 
microarray analysis. The results showed significant upregula-
tion (n=302) or downregulation (n=396) of 698 circRNAs 
in LSCC tissues. They further detected hsa_circ_100855 as 
the most upregulated circRNA and hsa_circ_104912 as the 
most downregulated circRNA using quantitative real-time-
PCR methods. Additionally, patients with T3–4 stages, 
neck nodal metastasis or advanced clinical stage had higher 
hsa_circ_100855 expression, and patients with T3–4 stages, 
neck nodal metastasis, poor differentiation or advanced 
clinical stage had a lower hsa_circ_104912 expression. 
Overall, their data suggest that circRNAs play an important 
role in the tumorigenesis of LSCC and may serve as novel 
and stable biomarkers for the diagnosis and progression of 
LSCC.27 Sand et al identified 23 upregulated and 48 down-
regulated circRNAs with 354 MREs capable of sequestering 
microRNA target sequences of the BCC miRNome through 
microarray circRNA expression profiles and described a 
variety of circRNAs that are potentially involved in the 
molecular pathogenesis of BCC.28
Conclusion and perspective
In the past, circRNAs were considered impossible to play a 
key role in the biological process because they were thought 
to be a byproduct of aberrant splicing events or interme-
diates that had escaped from intron lariat debranching. 
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Table 1 Literature of circRNAs and carcinomas
Type of cancer First author Received 
date
Journal Sequence name or 
more content
Expression
Cutaneous squamous cell carcinoma14 Sand M 2016/6/15 J Dermatol Sci Picking out 322 circRNAs cir­143↑, cir­179↓
BCC28 Sand M 2016/4/21 Epigenomics Screening out 71 circRNAs 23 circRNAs↑, 48 circRNAs↓
epithelial ovarian carcinoma29 Ahmed i 2016/4/28 Oncotarget Altered expression pattern Unclear
Ovarian carcinoma30 Bachmayr­Heyda A 2016/5/14 Oncotarget Unclear Unclear
Cervical cancer31 Abdelmohsen K 2017/1/13 RNA Biol CircPABPN1 (hsa_
circ_0031288)
Unclear




Hepatoma carcinoma32 Qin M 2015/11/26 Cancer Biomark hsa_circ_0001649 hsa_circ_0001649↓
Hepatoma carcinoma24 Yu L 2016/7/9 PLoS One circRNA Cdr1 circRNA Cdr1↑






Hepatoma carcinoma33 Xu L 2016/9/12 J Cancer Res 
Clin Oncol
ciRS­7 (Cdr1as) ciRS­7 (Cdr1as)↓
Pancreatic ductal carcinoma34 Qu S 2015/10/21 Genom Data Microarray expression 
profile
Unclear
Neuroglioma35 Song X 2016/2/14 Nucleic Acids 
Res
Screening out 476 
circRNAs
Unclear
Neuroglioma36 Barbagallo D 2015/12/20 Oncotarget Unclear Unclear
Neuroglioma37 Yang P 2016/9/11 Oncotarget cZNF292 circRNA cZNF292 circRNA↓
Colorectal cancer38 wang X 2016/2/18 Int J Clin Exp 
Pathol
hsa_circ_001988 hsa_circ_001988↓
Colorectal cancer, ovarian carcinoma39 Bachmayr­Heyda A 2015/1/28 Sci Rep The percent of circ/line The percent of circ/line↓
Colorectal cancer12 Xie H 2016/4/9 Oncotarget hsa_circ_001569 hsa_circ_001569↑
Colorectal cancer40 Huang G 2015/6/26 PLoS One cir­iTCH cir­iTCH↓
Colorectal cancer41 Zhu M 2017/1/20 Biomed 
Pharmacother
circ­BANP circ­BANP↑
KRAS mutant colon cancer42 Dou Y 2016/11/29 Sci Rep circRNA circRNA↓
Gastric carcinoma22 Li P 2015/2/18 Clin Chim Acta hsa_circ_002059 hsa_circ_002059↓
Gastric carcinoma43 Li P 2017/1/13 Br J Cancer hsa_circ_0000096 hsa_circ_0000096↓
Gastric carcinoma44 Chen S 2017/1/29 Clin Chim Acta hsa_circ_0000190 hsa_circ_0000190↓
esophageal carcinoma12 Xia w 2016/10/19 Sci Rep hsa_circ_0067934 hsa_circ_0067934↑














esophageal carcinoma21 Li F 2015/3/10 Oncotarget cir­iTCH cir­iTCH↓
Hematopoiesis malignancies46 Bonizzato A 2016/10/16 Blood Cancer J Screening out the 
expression of circRNAs
Unclear
Bladder carcinoma26 Zhong Z 2016/8/4 Sci Rep circTCF25 circTCF25↑
Bladder carcinoma47 Huang M 2016/7/1 Oncotarget circRNA M, YLK Unclear
Clear cell renal cell carcinoma48 wang K 2017/1/17 Cancer Lett circHiAT1 circHiAT1↓
Breast cancer49 Yang w 2015/12/15 Oncogene Foxo3 circRNA Foxo3 circRNA↑
Breast cancer50 Nair AA 2016/11/10 Oncotarget Unclear Unclear
Lung cancer23 wan L 2016/9/20 Biomed Res Int circRNA­iTCH circRNA­iTCH↓
Seven cancers51 Zheng Q 2016/4/7 Nat Commun circHiPK3 circHiPK3↓
Cancer52 Du ww 2016/2/11 Nucleic Acids 
Res
circ­Foxo3 circ­Foxo3↓
Cancer53 Hansen TB 2011/10/4 EMBO J CDR1 Unclear
Carcinoma54 Du ww 2016/11/26 Cell Death 
Differ
circ­Foxo3 circ­Foxo3↓
Notes: ↓ means downregulated. ↑ means upregulated.
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circRNAs in clinical application of carcinomas
technologies and bioinformatics, circRNAs were found to be 
broadly expressed and perform regulation in atherosclerotic 
vascular disease, neurological disorders, prion diseases and 
carcinomas. In summary, functional roles of circRNAs in 
the regulation of protein-coding gene expression through 
acting as microRNA sponges, regulating alternative splicing 
or transcription and modulating the expression of paren-
tal genes confer a great variety of functional potential to 
circRNAs. The fact that circRNAs are found abundant in 
clinical blood or tissue samples makes circRNA a promising 
diagnostic biomarker for cancer screening and prognostic 
evaluation.
Although the number of circRNAs with known functions 
is expanding, there are still thousands of circRNAs whose 
functions remain unknown. A deeper understanding of cir-
cRNA biogenesis may be needed to shed light on the road 
of functional consequences of circRNA.
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